FibroGen Inc (NAS:FGEN)
$ 1.3 0.02 (1.56%) Market Cap: 129.32 Mil Enterprise Value: 101.67 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 57/100

FibroGen Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 12, 2019 / 05:00PM GMT
Release Date Price: $40.2 (+1.98%)
Kyuwon Choi
Goldman Sachs Group Inc., Research Division - Equity Analyst

Okay, we'll continue with the next session. Good morning, everyone. I'm Paul Choi, the U.S. mid-cap biotechnology analyst here at Goldman Sachs. And in the audience here, from the team, we have Corinne Jenkins. Our next session will be with FibroGen. And to my left, from the management team, we have Dr. Tom Neff, CEO, who will introduce the rest of the team here for you to the audience.

Thomas B. Neff
FibroGen, Inc. - Founder, Chairman & CEO

Yes. Thank you, Paul. Dr. Peony Yu is on my immediate left, our Chief Medical Officer; and at the end, Dr. Elias Kouchakji, who is both Global Safety Head for the anemia program, roxadustat, and also the Head of Clinical Development for the pamrevlumab program. So that's the team for this morning.

Questions & Answers

Kyuwon Choi
Goldman Sachs Group Inc., Research Division - Equity Analyst

Great. Thank you for that. So perhaps we'll kick off the Q&A and -- with perhaps an overview of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot